Genprex (GNPX) Competitors $0.26 -0.01 (-4.07%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, SNYR, and CMMBShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), Synergy CHC (SNYR), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Its Competitors Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics FibroBiologics Klotho Neurosciences NanoViricides BioAtla Synergy CHC Chemomab Therapeutics GENPREX (NASDAQ:GNPX) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media refer more to GNPX or CARA? In the previous week, GENPREX's average media sentiment score of 0.00 equaled Cara Therapeutics'average media sentiment score. Company Overall Sentiment GENPREX Neutral Cara Therapeutics Neutral Which has better valuation and earnings, GNPX or CARA? GENPREX has higher earnings, but lower revenue than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENPREXN/AN/A-$21.11MN/AN/ACara Therapeutics$7.14M0.00-$118.51M-$21.01N/A Do insiders & institutionals hold more shares of GNPX or CARA? 14.1% of GENPREX shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 8.5% of GENPREX shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is GNPX or CARA more profitable? GENPREX has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets GENPREXN/A -664.65% -370.18% Cara Therapeutics -1,099.76%-367.97%-107.43% Which has more risk & volatility, GNPX or CARA? GENPREX has a beta of -0.5, suggesting that its stock price is 150% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. SummaryCara Therapeutics beats GENPREX on 5 of the 8 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.32M$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.7127.8120.25Price / SalesN/A283.26429.10119.26Price / CashN/A41.7026.2128.59Price / Book1.757.538.025.65Net Income-$21.11M-$55.14M$3.18B$249.15M7 Day Performance15.40%4.22%2.88%2.91%1 Month Performance-8.55%0.91%1.66%4.11%1 Year Performance-86.16%5.40%34.25%20.98% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex1.0451 of 5 stars$0.26-4.1%N/A-86.2%$7.32MN/A0.0020Gap DownCARACara Therapeutics0.3386 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2656 of 5 stars$5.76-1.5%$17.50+203.8%+88.0%$24.27MN/A-2.329LSTALisata Therapeutics2.4915 of 5 stars$2.90+3.6%$15.00+417.2%-24.8%$24.12M$1M-1.2630Positive NewsCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.5375 of 5 stars$0.62+0.7%$13.00+1,989.4%-87.0%$23.65MN/A0.0010Gap UpKLTOKlotho NeurosciencesN/A$1.13+56.9%N/AN/A$23.40MN/A0.00N/AAnalyst UpgradeHigh Trading VolumeNNVCNanoViricides1.0972 of 5 stars$1.40flatN/A-20.0%$22.50MN/A-1.9420News CoverageGap DownBCABBioAtla2.7307 of 5 stars$0.40+3.1%$5.00+1,162.6%-71.2%$22.43M$11M-0.3260Gap DownSNYRSynergy CHC3.757 of 5 stars$2.85+17.3%$10.00+250.9%N/A$22.34M$34.83M0.0040High Trading VolumeCMMBChemomab Therapeutics2.8921 of 5 stars$1.16-0.9%$8.50+632.8%+19.8%$22.06MN/A-1.5320Gap Up Related Companies and Tools Related Companies CARA Competitors TENX Competitors LSTA Competitors CYTH Competitors FBLG Competitors KLTO Competitors NNVC Competitors BCAB Competitors SNYR Competitors CMMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts